About Martine van Vugt | Senior Vice President, Genmab
Martine van Vugt is a senior executive with 20 years of biotechnology industry experience. A proven leader with successful track record of leading high performing global cross functional teams in a networked biotech environment. She is skilled in developing joint business value propositions, designing relationship structures and management of alliances. An Expert in corporate transactional and licensing operations, such as strategic partnering, in- and out-licensing, as well as asset divestment and purchases. She effectively blends analytical skills with a natural leadership style grounded in science and integrity. As Genmab’s SVP, Corporate Strategy and Planning and member of the Executive Committee, Martine leads the Corporate Strategy, Business Development and Alliance Management functions and manages the strategic agenda of the senior leadership team. Martine holds board positions at Immagene BV, Noxxon Pharma NV and Scandion Oncology.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX®, Arzerra, TEPEZZA®, Kesimpta® and DARZALEX FASPRO™. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies such as the DuoBody®, HexaBody® and the HexElect® platform. Genmab has alliances with top tier pharmaceutical and biotechnology companies and is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | |
|
© Copyright 2020 by Hyphen Projects